Journal of Mind and Medical Sciences
Volume 6 | Issue 1

Article 3

2019

The risk of bleeding and encephalopathy in surgical
patients with liver cirrhosis
Petrișor Banu
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Salvatore Settineri
University of Messina, Italy

Emanuele Maria Merlo
University of Messina, Italy

Maria Rosaria Anna Muscatello
University of Messina, Italy

Nicolae Bacalbașa
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
See next page for additional authors

Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Neurology Commons, Psychiatry Commons, Psychology Commons, and the Surgery
Commons

Recommended Citation
Banu, Petrișor; Settineri, Salvatore; Merlo, Emanuele Maria; Muscatello, Maria Rosaria Anna; Bacalbașa, Nicolae; Negrei, Carolina;
Gălățeanu, Bianca; Ghinghină, Octav; Păunica, Ioana; and Bălălău, Cristian (2019) "The risk of bleeding and encephalopathy in
surgical patients with liver cirrhosis," Journal of Mind and Medical Sciences: Vol. 6 : Iss. 1 , Article 3.
DOI: 10.22543/7674.61.P610
Available at: https://scholar.valpo.edu/jmms/vol6/iss1/3

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

The risk of bleeding and encephalopathy in surgical patients with liver
cirrhosis
Authors

Petrișor Banu, Salvatore Settineri, Emanuele Maria Merlo, Maria Rosaria Anna Muscatello, Nicolae Bacalbașa,
Carolina Negrei, Bianca Gălățeanu, Octav Ghinghină, Ioana Păunica, and Cristian Bălălău

This review article is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol6/iss1/3

Copyright © 2019. All rights reserved
https://scholar.valpo.edu/jmms/
https://proscholar.org/jmms/
ISSN: 2392-7674

J Mind Med Sci. 2019; 6(1): 6-10
doi: 10.22543/7674.61.P610

Received for publication: March 30, 2018
Accepted: June 21, 2018

Review
The risk of bleeding and encephalopathy in
surgical patients with liver cirrhosis
Petrișor Banu1,2, Salvatore Settineri3, Emanuele Maria Merlo3, Maria Rosaria
Anna Muscatello3, Nicolae Bacalbașa1, Carolina Negrei1, Bianca Gălățeanu4,
Octav Ghinghină1,5, Ioana Păunica1, Cristian Bălălău1,2
1

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
St. Pantelimon Clinical Emergency Hospital, Department of Surgery, Bucharest, Romania
3
University of Messina, Piazza Pugliatti, 1, 98122 Messina ME, Italy
4
The University of Bucharest, Department of Biochemistry and Molecular Biology, Bucharest, Romania
5
St. Ioan Clinical Emergency Hospital, Department of Surgery, Bucharest, Romania
2

Abstract
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Liver cirrhosis is a disease with an increasing incidence. Surgical procedures in
patients with cirrhosis are also increasing, due to a longer life expectancy in these
patients and also to the improvement of therapeutic and diagnostic resources.
Digestive hemorrhage in the cirrhotic patient requires emergency medical
intervention (intensive therapy, endoscopic or even surgical approaches), being at the
same time a factor that precipitates episodes of encephalopathy, i.e. the conventional
complication of cirrhosis. Hepatic encephalopathy represents one of the most severe
clinical events of cirrhosis, being associated with high morbidity and mortality. The
causes of hepatic encephalopathy are briefly presented in this paper. Therapeutic
approaches currently available consist in the administration of non-absorbable
disaccharides such as lactulose and non-absorbable antibiotics such as rifaximin. New
therapeutic perspectives are under evaluation, e.g. ammonia scavengers and the
modulation of gut microbiota.
Clotting disorders in patients with liver cirrhosis are more severe as the disease
progresses and involves complex mechanisms, as presented in this review. The
correction of possible disorders of hemostasis should be promptly made as a sine qua
non condition prior to surgery.
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 It is difficult to determine the hemostatic profile of cirrhotic patients only by running the
usual laboratory tests, due to the existence of a fragile balance between hypo- and
hypercoagulability factors.
 Most cases of hepatic encephalopathy are precipitated by events such as digestive
hemorrhage and infections, which must be carefully monitored to prevent
encephalopathy in cirrhotic patients as much as possible.
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Introduction
In the last decades, there has been a spectacular
increase in the life expectancy of patients with liver
cirrhosis thanks to the improvement of therapeutic and
diagnostic resources. On the background of these data, but
also because of the increase in cirrhotic incidence, the
number of surgical procedures in patients with cirrhosis is
also increasing. Due to limited cases that are suited for
liver transplantation, the medical and surgical therapeutic
approaches focus especially on complications, which have
become the main concern of the long-term management
of cirrhosis (1).
One of the mandatory requirements for the cirrhotic
patient who is about to undergo surgery is the evaluation
of the hemostatic profile, since liver cirrhosis is
accompanied by clotting disorders that increase as the
disease progresses. The correction of the possible
disorders of hemostasis should be promptly made as a
sine qua non condition prior to surgery (2).
Clinically, hemostatic disorders are revealed by the
presence of bruises, purpura, epistaxis or gingivorrhagia.
Hemostatic abnormalities in cirrhosis are multifactorial.
They are a consequence of the decreasing capacity of
hepatocyte synthesis, reticuloendothelial dysfunction and
portal hypertension (3).
Hepatic encephalopathy (HE) is a relatively frequent
complication encountered especially in the advanced
stages of cirrhosis. HE is expressed through several
(neuropsychiatric, neuromuscular, metabolic etc.)
dysfunctions. According to literature, minor HE affects up
to 60-70% of patients with cirrhosis to a certain extent.
Although many patients with minor HE (subtle alterations
of the cognitive functions) seem to be clinically
asymptomatic, the condition has a considerable impact on
the patients’ life quality, such as poor driving
performance, an increased risk of falls, predispositions to
hospitalizations and even death (4).
Severe HE usually implies more severe signs and
symptoms, represented by alterations in consciousness,
temporal and spatial disorientation, behavioral and
emotional changes, and generalized motor dysfunction.
During its evolution, this form of HE is encountered in
about 30–45% of patients with cirrhosis, representing a
significant cause of hospitalizations for patients with poor
evolution and prognosis (5).
Possible precipitating
factors of HE
are
gastrointestinal bleedings, bacterial infections, and
accumulation of gut-derived toxins (especially ammonia).
All these factors (causing inflammation and oxidative

stress) lead to cerebral edema, which underlies the core
symptoms of HE (6).

Discussions
For a long time, it has been assumed that the decrease
in circulating platelets is due to hypersplenism. In 1967,
Aster and Jandl correlated splenomegaly in portal
hypertension with extensive platelets pooling which
would cause thrombocytopenia (1, 3).
However, this assumption does not explain all the
platelet changes and it is contradicted by a few
observations. Splenomegaly in cirrhosis is not in a linear
relation with the degree of portal hypertension, but it is
rather the effect of parenchymal hypertrophy. On the
other hand, surgical procedures to reduce portal
hypertension, such as portacaval shunt, do not directly
lead the increase of circulating platelet count (4, 5).
Radio labeled platelet studies showed that there is a
shortening of the life span of platelets in liver cirrhosis.
Thrombocytolysis occurs through an immunological
mechanism proven by the presence of increased
concentrations of autoantibodies in the serum against a
major platelet antigen, GP IIb / IIIa. These antibodies are
produced by B lymphocytes, the proportion of which
increases (7).
Maintenance of platelet counts within normal limits
depends on the ability of bone marrow to increase
production, which is reflected in the proportion of young
elements in the circulation. Although thrombocytopoiesis
is under the direct effect of thrombopoietin, a growth
factor synthesized mainly by the liver and the kidney, and
whose serum levels decrease in advanced cirrhosis and
portal hypertension, its titers do not correlate directly with
medullary platelets synthesis (8).
This apparent discordance results from the fact that
the removal of thrombopoietin from the circulation is
made through its internalization in megakaryocytes and
platelets, including those which are pooled in the spleen
(9). In liver cirrhosis, platelets also show quantitative
changes besides decreasing in number (10).
The observed hypo-aggregability has complex
mechanisms, which include both platelet factors and
plasma factors. On the one hand, there is a
transmembrane signaling the defect after stimulation with
thrombin or collagen and thus a decrease in intracellular
messengers, and, on the other hand, a number of plasma
factors that have a negative effect on aggregability. The
latter includes: bile salts, fibrinogen degradation products,
HDL or apolipoprotein E (6-8).
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Preoperative thrombocytopenia requires correction by
platelet transfusion to achieve a platelet level which can
be considered safe depending on the type of surgical
intervention. Minor surgical procedures with a low
bleeding risk can be safely performed with platelet count
>50 000/mm3, while major surgery requires a minimum
platelet count of 100,000/mm3 (11).
Coagulation disorders in the cirrhotic patient may
occur not only in the context of quantitative and
qualitative changes in platelets, but also in the reduction
of coagulation factors. Most of them are synthesized in
the hepatocyte, except factor VIII (12).
The usual laboratory tests, prothrombin time (PT) and
activated partial thromboplastin time (APTT), indicate a
degree of hypercoagulability in patients with advanced
diseases, but they do not objectively reflect their
hemostatic profile. Recent studies suggest that there is a
balance, albeit precarious in cirrhosis, between hypo- and
hypercoagulability resulting from deficiencies in the
synthesis of both pro-coagulant and anti-coagulant factors
(13, 14).
In cirrhosis, there is a deficiency in the synthesis of
vitamin K-dependent coagulation factors, II, VII, IX and
X, which result from the decrease in hepatocyte
production capacity and from the decrease in vitamin
absorption in the intestinal lumen due to the antibiotic
treatment which reduces the bacterial flora that produces
it, the decrease in vitamin K synthesis or cholestasis (15).
Besides, there are also abnormalities of fibrinolysis
due to the alteration of the synthesis of fibrinolytic
factors, but also their clearance, for which the
reticuloendothelial system of the liver is mainly
responsible. Thus, one can see an imbalance between the
plasminogen tissue activator and its inhibitor PAI1,
resulting in a fibrinolysis deficiency which is amplified by
a decreased clearance of circulating activated coagulation
factors (16).
The protein synthesis deficiency also influences the
production of anticoagulant factors, especially protein C
and its cofactor, protein S, whose role in vivo is to reduce
thrombin production by inhibiting Factors Va and VIIa
(17).
Given the apparent hypocoagulability present in
cirrhosis, which can be revealed by the usual laboratory
tests, PT and APTT, it is considered that this category of
patients is somewhat “protected” against the risk of
thrombosis (16, 18).
However, clinical observations show a considerable
incidence of thrombosis in advanced cirrhosis, especially
in portal and mesenteric veins. In addition to
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hypercoagulability, whose causes have been exposed
above, Virchow Triad is complemented by hemodynamic
changes in these cases, consisting in slowing down the
blood flow through portal hypertension and vascular wall
alterations (19).
In addition, there are factors that further contribute to
the progression of hepatic cirrhosis such as the formation
of intraparenchymatous microthrombi caused by ischemia
and the activation of stellate cells by thrombin (20).
The deficiencies of the factors involved in hemostasis
affect all its sequences, which leads to the occurrence of
balance, but more fragile than in normal conditions,
between hypo- and hypercoagulability: the procoagulant
protein deficiency is offset due to the deficiency of
proteins C and S, fibrinolysis is balanced by the
concomitant deficiency of antifibrinolytics and the
qualitative and quantitative deficiencies of platelets are
offset by the increase in plasma levels of von Willebrand
factor and a protein which stimulates platelet adhesion
(21, 22).
The hemostatic profile of cirrhotic patients is therefore
difficult to determine only by running the usual laboratory
tests, but given the experience of liver transplantation
centers, one can recommend major surgery even in
patients with cirrhosis who are apparently in a state of
hypocoagulability, without the risk of major incidents
(14). Until the validation of these data, in patients
undergoing surgery, the correction of coagulation deficits
is practically mandatory (23).
Enteric bacterial translocation is favored in patients
with cirrhosis, being influenced by immunological
impairment/ presence of intestinal bacterial overgrowth,
and increased intestinal permeability. This bacterial
translocation increases the levels of systemic gut-derived
toxins (especially in the presence of portosystemic shunt),
thus having an important role in the development of HE.
Moreover, bacterial translocation increases the risk of
abdominal infection (bacterial peritonitis, septicemia),
which negatively influence morbidity and mortality in
patients with cirrhosis (24, 25).
Although the pathophysiological mechanisms
involved in hepatic encephalopathy (HE) are not yet fully
elucidated, literature data show that an increased
accumulation of gut-derived toxins (ammonia and other
derivatives), represents the main factors which determine
HE. The accumulation of toxins (from bacteria,
inflammation and oxidative stress) is the consequence of
decreased liver function on one hand, and due to
development of portosystemic shunts (which diminish the
liver capacity to remove toxins from the blood-stream) on
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the other hand. All these mechanisms are responsible (at
least in part) for cerebral edema, which represents the
main substrate of HE (26).
Most cases of hepatic encephalopathy are precipitated
by
events
such
as
digestive
hemorrhage,
hydroelectrolytic/ acido-basal imbalance, infections,
sedation, constipation or diarrhea, etc. This means that a
good monitoring/ control of the hemostatic profile of
cirrhotic patients can reduce the rate of digestive bleeding
in these patients, and thus reduces the number/severity of
hepatic encephalopathies (27-29).

Conclusions
Hemostasis disorders in patients with liver cirrhosis
have complex mechanisms and are more severe in the
advanced stages of the disease. In patients with cirrhosis,
there is a relative precarious balance between hypo- and
hypercoagulability, which is caused by deficiencies in the
synthesis of both procoagulant and anti-coagulant factors.
Hepatic encephalopathy, variceal bleeding, jaundice
and ascites, are diagnostic elements of decompensated
cirrhosis, which is associated with high mortality rates if
the patient does not benefit from liver transplantation.
Decompensated cirrhosis should be delineated by acuteon-chronic liver failure (ACLF), represented by a chronic
liver disease (in patients with or without cirrhosis) that
presents a rapid decline (hepatic and extra-hepatic organ
failures) due to the intervention of several precipitating
factors.
The risk of bleeding is correlated with the type of
surgery in cirrhotic patients, but prior to the surgical
procedure it is mandatory to correct the clotting disorders
in order to minimize the risk of intraoperative bleeding.
For this purpose, the already existing diagnostic,
monitoring and treatment protocols for cirrhotic patients
should be improved. For example, a very recent protocol
for end-stage liver disease proved to be able to evaluate
morbidity and mortality more accurately than the older
prognostic models in cirrhotic patients (30).
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